EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference
September 15, 2022 08:00 ET
|
Novan, Inc.
– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis ...
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 06:30 ET
|
Novan, Inc.
– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the...
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
August 04, 2022 09:05 ET
|
Novan, Inc.
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday,...
Novan Satisfies $16.5 Million Outstanding Promissory Note
July 19, 2022 08:30 ET
|
Novan, Inc.
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations – – Novan saves $11.1 million in principal and...
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
June 13, 2022 16:05 ET
|
Novan, Inc.
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering...
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
June 09, 2022 08:30 ET
|
Novan, Inc.
DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to...
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
May 19, 2022 09:05 ET
|
Novan, Inc.
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of...
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 06:30 ET
|
Novan, Inc.
– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1 2021 – – Ongoing activities toward...
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
May 06, 2022 09:00 ET
|
Novan, Inc.
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May...
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event
April 20, 2022 09:05 ET
|
Novan, Inc.
DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology...